




# MOLECULAR GENETICS AND METABOLISM

Is the official journal of the [Society for Inherited Metabolic Disorders](#)

## AUTHOR INFORMATION PACK

### TABLE OF CONTENTS

●	<b>Description</b>	<b>p.1</b>
●	<b>Audience</b>	<b>p.2</b>
●	<b>Impact Factor</b>	<b>p.2</b>
●	<b>Abstracting and Indexing</b>	<b>p.2</b>
●	<b>Editorial Board</b>	<b>p.2</b>
●	<b>Guide for Authors</b>	<b>p.3</b>



ISSN: 1096-7192

### DESCRIPTION

*Molecular Genetics and Metabolism* is a contribution to the understanding of the **metabolic basis of disease**. The journal publishes articles describing investigations that use the tools of **biochemistry** and **molecular biology** for studies of normal and diseased states. In addition to original research articles, occasional minireviews reporting timely advances as well as brief communications and letters to the editor are considered.

Research Areas include:

- **Inherited Metabolic Diseases:**
  - Biochemical studies of primary enzyme defects
  - Molecular genetic analyses of mutations
  - Pathogenesis of these disorders, including not only primary but also secondary metabolic alterations
- **Systems Biology:**
  - Functional integration of biochemical network modules
  - Moonlighting functions of proteins
- **Intercellular and Intracellular Metabolic Relationships:**
  - Biochemical interactions between cells
  - Functional roles of and interactions between subcellular compartments and distinct regions within these cellular spaces, termed microcompartments
  - Metabolic relations between individual enzymes and pathways
- **Cellular Catalysts:**
  - Protein and nonprotein catalyst in normal and deranged cellular metabolism
  - Relationships between the structure and function of catalytic molecules
  - Interaction of these catalysts with other cellular components
- **Disease Pathogenesis:**
  - Underlying mechanisms of inherited and acquired diseases
  - Relationships between genotype and phenotype at the biochemical and molecular levels
- **Treatment:**
  - Drug, protein and dietary interventions
  - Transplantation and gene therapy
  - Multicenter clinical trials

Advances in nanomedicine, nanopediatrics and nanotechnology are also welcome.

## AUDIENCE

---

Molecular geneticists, biochemical geneticists, endocrinologists, metabolists, biochemists, molecular biologists

## IMPACT FACTOR

---

2013: 2.827 © Thomson Reuters Journal Citation Reports 2014

## ABSTRACTING AND INDEXING

---

EMBASE  
Scopus  
EMbiology

## EDITORIAL BOARD

---

### *Editor-in-Chief:*

**Edward McCabe**, March of Dimes, White Plains, New York, USA

### *Managing Editor:*

**Linda McCabe**, University of Colorado School of Medicine, Aurora, Colorado, USA

### *Editorial Board:*

**Rivka Beitner**, Bar-Ilan University, Ramat Gan, Israel

**Mike Bennett**, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

**Nenad Blau**, Universitätsspital Zürich, Zürich, Switzerland

**Robert Desnick**, Mount Sinai School of Medicine, New York, New York, USA

**Orly Elpeleg**, Hebrew University Hadassah Medical School, Jerusalem, Israel

**Fumio Endo**, Kumamoto University, Kumamoto, Japan

**Yoshikatsu Eto**, Tokyo Jikei University of Medicine, Tokyo, Japan

**William Gahl**, National Human Genome Research Institute (NHGRI), Bethesda, Maryland, USA

**Stephen Goodman**, University of Colorado Health Sciences Center, Denver, Colorado, USA

**Gregory Grabowski**, Children's Hospital Medical Center, Cincinnati, Ohio, USA

**John Hopwood**, Adelaide Children's Hospital, North Adelaide, South Australia, Australia

**Jeff Innis**, University of Michigan Medical School, Ann Arbor, Michigan, USA

**Priya Kishnani**

**Brendan Lee**, Baylor College of Medicine, Houston, Texas, USA

**Yoichi Matsubara**, National Center for Child Health and Development (Japan), Tokyo, Japan

**Roderick McInnes**, Jewish General Hospital (JGH), Montréal, Quebec, Canada

**Patricia McLean**, University College London (UCL), London, UK

**Walter Miller**, University of California at San Francisco (UCSF), San Francisco, California, USA

**Maximilian Muenke**, National Human Genome Research Institute (NHGRI), Bethesda, Maryland, USA

**Arnold Munnich**, Hôpital Necker - Enfants Malades, Paris, France

**Torayuki Okuyama**, National Center for Child Health and Development (Japan), Tokyo, Japan

**Ferdinando Palmieri**, Università degli Studi di Bari, Bari, Italy

**Piero Rinaldo**, Mayo Clinic, Rochester, Minnesota, USA

**William Rizzo**, University of Nebraska Medical Center (UNMC), Omaha, Nebraska, USA

**Charles Roe**, Baylor College of Medicine, Dallas, Texas, USA

**Rima Rozen**, Montreal Children's Hospital, Montreal, Quebec, Canada

**Charles Scriver**, McGill University, Montréal, Canada

**Ellen Sidransky**, National Human Genome Research Institute (NHGRI), Bethesda, Maryland, USA

**Flemming Skovby**, Rigshospitalet, København, Denmark

**Brage Storstein Andresen**, University of Southern Denmark, Odense, Denmark

**Mendel Tuchman**, Children's National Medical Center, Washington, District of Columbia, USA

**Jerry Vockley**, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

**Ronald Wanders**, Universiteit van Amsterdam, Academisch Medisch Centrum (AMC), Amsterdam Zuidoost, Netherlands

**Barry Wolf**, Henry Ford Hospital, Detroit, Michigan, USA

**Philip Wood**, Sanford-Burnham Medical Research Institute, Orlando, Florida, USA

### *Founding Editor:*

**Bessman**

## GUIDE FOR AUTHORS

---

### *Your Paper Your Way*

We now differentiate between the requirements for new and revised submissions. You may choose to submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when your paper is at the revision stage, will you be requested to put your paper in to a 'correct format' for acceptance and provide the items required for the publication of your article.

**To find out more, please visit the Preparation section below.**

### INTRODUCTION

Molecular Genetics and Metabolism is a contribution to the understanding of the metabolic basis of disease. The journal publishes articles describing investigations that use the tools of biochemistry and molecular biology for studies of normal and diseased states.

Research Areas include:

- Inherited Metabolic Diseases
  - Biochemical studies of primary enzyme defects
  - Molecular genetic analyses of mutations
  - Pathogenesis of these disorders, including not only primary but also secondary metabolic alterations
- Systems Biology
  - Functional integration of biochemical network modules
  - Moonlighting functions of proteins
- Intercellular and Intracellular Metabolic Relationships
  - Biochemical interactions between cells
  - Functional roles of and interactions between subcellular compartments and distinct regions within these cellular spaces, termed microcompartments
  - Metabolic relations between individual enzymes and pathways
- Cellular Catalysts
  - Protein and nonprotein catalyst in normal and deranged cellular metabolism
  - Relationships between the structure and function of catalytic molecules
  - Interaction of these catalysts with other cellular components
- Disease Pathogenesis
  - Underlying mechanisms of inherited and acquired diseases
  - Relationships between genotype and phenotype at the biochemical and molecular levels
- Treatment
  - Drug, protein and dietary interventions
  - Transplantation and gene therapy
  - Multicenter clinical trials
  - Pharmacogenetics / Pharmacogenomics

Submitted manuscripts claiming to be a demonstration of a new mutation will be rejected and returned to authors without review unless the authors present results of a search for the new mutation in at least 100 chromosomes from unaffected individuals of the same ethnic background as the patient(s) with the new mutation.

Authors should perform a power calculation to determine how many subjects they need to study in order to find a significant association between a sequence variation and a disorder. The results of the power calculation should be included in the methods section of the manuscript. Submitted manuscripts without a power calculation will be rejected and returned to authors without review.

Authors attempting to demonstrate genotype/phenotype correlation should review the literature below to help them interpret their results:

R. Dorfman, A. Sandford et al., Complex two-gene modulation of lung disease severity in children with cystic fibrosis, *J. Clin. Invest.* 118 (2008) 1040-1049,  
<http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2248329>.

K.M. Dipple, E.R.B. McCabe, Modifier genes convert "simple" Mendelian disorders to complex traits, *Mol. Genet. Metab.* 71 (2000) 43-50.

K.M. Dipple, E.R.B. McCabe, Phenotypes of patients with "simple" Mendelian disorders are complex traits: Thresholds, modifiers, and systems dynamics. *Am. J. Hum. Genet.* 66 (2000) 1729-1735.

K.M. Dipple, J.K. Phelan, E.R.B. McCabe, Consequences of complexity within biological networks: Robustness and health, or vulnerability and disease. *Mol. Genet. Metab.* 74 (2001) 45-50.

C.R. Scriver, P.J. Waters, Monogenic traits are not simple: Lessons learned from phenylketonuria. *Trends Genet.* 15 (1999) 267-272.

J. Vockley, P. Rinaldo, M.J. Bennett, G.D. Vladutiu, Synergistic heterozygosity: Disease resulting from multiple partial defects in one or more metabolic pathways. *Mol. Genet. Metab.* 71 (2000) 10-18.

### **Types of paper**

In addition to original research articles, occasional minireviews reporting timely advances as well as brief communications and letters to the editor are considered.

*Original articles* will be considered on the basis of the originality and quality of the work, the clarity of the presentation, and the relevance of the research to the goal of the journal. At the discretion of the Editor, an original article may be accompanied by a Commentary by a member of the Editorial Board or another contributor.

*Minireviews* will describe timely advances within the scope of the journal, emphasizing emerging topical areas and/or critically analyzing existing data. Contributors should communicate with the Editor before preparing or submitting a review in order to determine if the topic and intent are considered appropriate. At the discretion of the Editor, reviews may be accompanied by comment from one of the Editors or another contributor. Minireviews may be any length and may include any number of references. Figures and tables may be included.

*Brief Communications* will be considered for publication with an expedited review. These short manuscripts should be no more than 5 manuscript pages (approximately 1000 words) in length with a limit of one figure or table. Standard section headings should be utilized and the abstract should be limited to a few sentences (75 words or less).

*Letters to the Editor* will be considered for rapid publication if they lie within the purview of the journal and if they contain new information, comment on published work, or new theoretical suggestions. These should be brief (300 words or less) and without subject headings. One table or figure will be allowed. Please add the following "types of paper" (you can just add it as the last type of paper):

*Data in Brief*: Authors have the option of converting any or all parts of their supplementary data into one or multiple Data in Brief articles, a new kind of article that houses and describes their data. Data in Brief articles ensure that your data, which is normally buried in supplementary material, is actively reviewed, curated, formatted, indexed, given a DOI and publicly available to all upon publication. Data in Brief may be submitted directly to the Molecular Genetics and Metabolism alongside a research article. Authors are encouraged to convert their supplementary data into a Data in Brief article when they submit a revised version of their manuscript to the Molecular Genetics and Metabolism. If your research article is accepted, your Data in Brief article will be editorially reviewed and published in the new, open access journal, *Data in Brief*. The [Open Access fee for Data in Brief](#) in 2015 is \$250. Please directly contact the publisher to request any need-based waivers or discounts.

Please use the following [template](#) to write your Data in Brief.

### **Contact details for submission**

Please submit your articles via the journal's online submission and editorial system: <http://ees.elsevier.com/mgm/>

### **Customer support is available 24/7:**

Please use our help site at: <http://epsupport.elsevier.com/>. Here you will be able to learn more about online submission system via interactive tutorials, explore a range of common problem solutions via our knowledgebase, and find answers to frequently asked questions. You will also find our 24/7 support contact details should you need any assistance from one of our customer service representatives.

## Questions on submission and reviewing process:

Please contact the Editorial Office at [MoGenMetab@elsevier.com](mailto:MoGenMetab@elsevier.com).

## BEFORE YOU BEGIN

### **Ethics in publishing**

For information on Ethics in publishing and Ethical guidelines for journal publication see <http://www.elsevier.com/publishingethics> and <http://www.elsevier.com/journal-authors/ethics>.

### **Human and animal rights**

If the work involves the use of animal or human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans <http://www.wma.net/en/30publications/10policies/b3/index.html>; EU Directive 2010/63/EU for animal experiments [http://ec.europa.eu/environment/chemicals/lab\\_animals/legislation\\_en.htm](http://ec.europa.eu/environment/chemicals/lab_animals/legislation_en.htm); Uniform Requirements for manuscripts submitted to Biomedical journals <http://www.icmje.org>. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

### **Conflict of interest**

*Molecular Genetics and Metabolism* follows the ICMJE recommendations regarding conflict of interest disclosures. All authors are required to report the following information with each submission: (1) All third-party financial support for the work in the submitted manuscript. (2) All financial relationships with any entities that could be viewed as relevant to the general area of the submitted manuscript. (3) All sources of revenue with relevance to the submitted work who made payments to you, or to your institution on your behalf, in the 36 months prior to submission. (4) Any other interactions with the sponsor of outside of the submitted work should also be reported. (5) Any relevant patents or copyrights (planned, pending, or issued). (6) Any other relationships or affiliations that may be perceived by readers to have influenced, or give the appearance of potentially influencing, what you wrote in the submitted work. As a general guideline, it is usually better to disclose a relationship than not. This information will be acknowledged at publication in a Transparency Document link directly in the article. Additional information on the ICMJE recommendations can be found at: <http://www.icmje.org/>. The form for conflict of interest disclosure can be downloaded here: [http://www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) (if this link does not display properly in your browser, please right-click the link and select "Save Target As..." or "Save Link as..." from the pop-up menu).

### **Submission declaration**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see <http://www.elsevier.com/postingpolicy>), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere including electronically in the same form, in English or in any other language, without the written consent of the copyright-holder.

### **Changes to authorship**

This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:

*Before the accepted manuscript is published in an online issue:* Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed.

*After the accepted manuscript is published in an online issue:* Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.

## Copyright

This journal offers authors a choice in publishing their research: Open access and Subscription.

### *For subscription articles*

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright, see <http://www.elsevier.com/copyright>). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations (please consult <http://www.elsevier.com/permissions>). If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult <http://www.elsevier.com/permissions>.

### *For open access articles*

Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (for more information see <http://www.elsevier.com/OAauthoragreement>). Permitted reuse of open access articles is determined by the author's choice of user license (see <http://www.elsevier.com/openaccesslicenses>).

## Retained author rights

As an author you (or your employer or institution) retain certain rights. For more information on author rights for:

Subscription articles please see <http://www.elsevier.com/journal-authors/author-rights-and-responsibilities>.  
Open access articles please see <http://www.elsevier.com/OAauthoragreement>.

## Role of the funding source

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

## Funding body agreements and policies

Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit <http://www.elsevier.com/fundingbodies>.

## Open access

This journal offers authors a choice in publishing their research:

### **Open access**

- Articles are freely available to both subscribers and the wider public with permitted reuse
- An open access publication fee is payable by authors or their research funder

### **Subscription**

- Articles are made available to subscribers as well as developing countries and patient groups through our access programs (<http://www.elsevier.com/access>)
- No open access publication fee

All articles published open access will be immediately and permanently free for everyone to read and download. Permitted reuse is defined by your choice of one of the following Creative Commons user licenses:

**Creative Commons Attribution (CC BY):** lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine



the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

**Creative Commons Attribution-NonCommercial-ShareAlike (CC BY-NC-SA):** for non-commercial purposes, lets others distribute and copy the article, to create extracts, abstracts and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text and data mine the article, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, do not modify the article in such a way as to damage the author's honor or reputation, and license their new adaptations or creations under identical terms (CC BY-NC-SA).

**Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND):** for non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

To provide open access, this journal has a publication fee which needs to be met by the authors or their research funders for each article published open access.

Your publication choice will have no effect on the peer review process or acceptance of submitted articles.

The open access publication fee in this journal is **\$2200**, excluding taxes. Learn more about Elsevier's pricing policy: <http://www.elsevier.com/openaccesspricing>.

### **Language (usage and editing services)**

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop (<http://webshop.elsevier.com/languageediting/>) or visit our customer support site (<http://support.elsevier.com>) for more information.

### **Submission**

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

### **Referees**

Please submit the names and institutional e-mail addresses of several potential referees. For more details, visit our [Support site](#). Note that the editor retains the sole right to decide whether or not the suggested reviewers are used.

## **PREPARATION**

### **NEW SUBMISSIONS**

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process.

As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or layout that can be used by referees to evaluate your manuscript. It should contain high enough quality figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.

### **References**

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.

## Formatting requirements

There are no strict formatting requirements but all manuscripts must contain the essential elements needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and Methods, Results, Conclusions, Artwork and Tables with Captions.

If your article includes any Videos and/or other Supplementary material, this should be included in your initial submission for peer review purposes.

Divide the article into clearly defined sections.

### *Figures and tables embedded in text*

Please ensure the figures and the tables included in the single file are placed next to the relevant text in the manuscript, rather than at the bottom or the top of the file.

## REVISED SUBMISSIONS

### *Use of word processing software*

Regardless of the file format of the original submission, at revision you must provide us with an editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier: <http://www.elsevier.com/guidepublication>). See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

## Article structure

### *Subdivision - numbered sections*

Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.

### *Introduction*

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

### *Material and methods*

Provide sufficient detail to allow the work to be reproduced. Methods already published should be indicated by a reference: only relevant modifications should be described.

### *Results*

Results should be clear and concise.

### *Discussion*

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

### *Conclusions*

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

### *Appendices*

If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

## Essential title page information

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.

- **Author names and affiliations.** Where the family name may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.



• **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. **Ensure that phone numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address. Contact details must be kept up to date by the corresponding author.**

• **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

### **Abstract**

A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

### **Keywords**

Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

### **Abbreviations**

Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

### **Acknowledgements**

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

### **Nomenclature and units**

Whenever **enzymes** are the subject of reporting, the Enzyme Commission (EC) number should be used for accurate identification and retrieval purposes. The Internet address for the Enzyme Commission is <http://www.bis.med.jhmi.edu/bio/search/FILT/enzyme.html>.

### **Database linking**

Elsevier encourages authors to connect articles with external databases, giving their readers one-click access to relevant databases that help to build a better understanding of the described research. Please refer to relevant database identifiers using the following format in your article: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN). See <http://www.elsevier.com/databaselinking> for more information and a full list of supported databases.

### **Genbank**

**DNA sequences and GenBank accession numbers.** Whenever nucleic acid and/or protein sequence information is presented, an accession number from EMBL/GenBank or NBRF should be submitted. Authors wishing to enable other scientists to use the accession numbers cited in their papers via links to these sources, should type this information in the following manner: For each and every accession number cited in an article, authors should type the accession number in bold, underlined text. Letters in the accession number should always be capitalized (see example below). This combination of letters and format will enable the typesetter to recognize the relevant texts as accession numbers and add the required link to the GenBank sequences.

Example: GenBank accession nos. **AI631510** , **AI631511** , **AI632198** , and **BF223228** ), a B-cell tumor from a chronic lymphatic leukemia (GenBank accession no. **BE675048** ), and a T-cell lymphoma (GenBank accession no. **AA361117** ).

Authors are encouraged to check accession numbers used very carefully. An error in a letter or number can result in a dead link. In the final version of the *printed article*, the accession number text will not appear bold or underlined. In the final version of the *electronic copy*, the accession number text will be linked to the appropriate source in the NCBI databases, enabling readers to go directly to that source from the article.

**Human gene mutations** should be named in accord with the recommendations of the Nomenclature Working Group (Antonarakis et al., Hum. Mutat. 11 (1998) 1-3; den Dunnen and Antonarakis, Hum. Mutat. 15 (2000) 7-12).

### **Math formulae**

Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

### **Footnotes**

Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors build footnotes into the text, and this feature may be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article.

### **Artwork**

#### *Electronic artwork*

#### *General points*

- Make sure you use uniform lettering and sizing of your original artwork.
  - Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
  - Number the illustrations according to their sequence in the text.
  - Use a logical naming convention for your artwork files.
  - Indicate per figure if it is a single, 1.5 or 2-column fitting image.
  - For Word submissions only, you may still provide figures and their captions, and tables within a single file at the revision stage.
  - Please note that individual figure files larger than 10 MB must be provided in separate source files.
- A detailed guide on electronic artwork is available on our website:

<http://www.elsevier.com/artworkinstructions>.

**You are urged to visit this site; some excerpts from the detailed information are given here.**

#### *Formats*

Regardless of the application used, when your electronic artwork is finalized, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.

TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.

TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.

TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.

#### **Please do not:**

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
- Supply files that are too low in resolution.
- Submit graphics that are disproportionately large for the content.

#### *Color artwork*

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. **For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article.** Please indicate your preference for color: in print or online only. For further information on the preparation of electronic artwork, please see <http://www.elsevier.com/artworkinstructions>.

Please note: Because of technical complications that can arise by converting color figures to 'gray scale' (for the printed version should you not opt for color in print) please submit in addition usable black and white versions of all the color illustrations.

#### *Figure captions*

Ensure that each illustration has a caption. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

#### **Tables**

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules.

#### **References**

##### *Citation in text*

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

##### *Web references*

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

##### *References in a special issue*

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

##### *Reference management software*

This journal has standard templates available in key reference management packages EndNote (<http://www.endnote.com/support/enstyles.asp>) and Reference Manager (<http://refman.com/support/rmstyles.asp>). Using plug-ins to wordprocessing packages, authors only need to select the appropriate journal template when preparing their article and the list of references and citations to these will be formatted according to the journal style which is described below.

##### *Reference formatting*

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

##### *Reference style*

*Text:* Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given.

Example: '..... as demonstrated [3,6]. Barnaby and Jones [8] obtained a different result ....'

*List:* Number the references (numbers in square brackets) in the list in the order in which they appear in the text.

##### *Examples:*

Reference to a journal publication:

[1] J. van der Geer, J.A.J. Hanraads, R.A. Lupton, The art of writing a scientific article, *J. Sci. Commun.* 163 (2010) 51–59.

Reference to a book:

[2] W. Strunk Jr., E.B. White, *The Elements of Style*, fourth ed., Longman, New York, 2000.

Reference to a chapter in an edited book:

[3] G.R. Mettam, L.B. Adams, How to prepare an electronic version of your article, in: B.S. Jones, R.Z. Smith (Eds.), *Introduction to the Electronic Age*, E-Publishing Inc., New York, 2009, pp. 281–304.

*Journal abbreviations source*

Journal names should be abbreviated according to the List of Title Word Abbreviations: <http://www.issn.org/services/online-services/access-to-the-ltwa/>.

### **Video data**

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a preferred maximum size of 50 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages at <http://www.elsevier.com/artworkinstructions>. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

### **AudioSlides**

The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. More information and examples are available at <http://www.elsevier.com/audioslides>. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

### **Supplementary data**

Elsevier accepts electronic supplementary material to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>. In order to ensure that your submitted material is directly usable, please provide the data in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit our artwork instruction pages at <http://www.elsevier.com/artworkinstructions>.

Alternatively, authors may convert any or all parts of their supplementary data into one or multiple Data in Brief articles, a new kind of article that houses and describes their data. Data in Brief articles ensure that your data, which is normally buried in supplementary material, is actively reviewed, curated, formatted, indexed, given a DOI and publicly available to all upon publication. You can submit your Data in Brief directly alongside your research article submission (either initially or at the revision stage). If your research article is accepted, your Data in Brief article will be editorially reviewed and published in the new, Open Access journal, *Data in Brief*. Your Data in Brief and research article will directly cite and link to each other (see published [examples](#)). The open access fees will be waived if your article is submitted by December 31, 2014.

Please use the following [template](#) to write your Data in Brief.

### **Submission checklist**

The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.

#### **Ensure that the following items are present:**

One author has been designated as the corresponding author with contact details:

- E-mail address

- Full postal address
- Telephone

All necessary files have been uploaded, and contain:

- Keywords
- All figure captions
- All tables (including title, description, footnotes)

Further considerations

- Manuscript has been 'spell-checked' and 'grammar-checked'
- All references mentioned in the Reference list are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)

Printed version of figures (if applicable) in color or black-and-white

- Indicate clearly whether or not color or black-and-white in print is required.
- For reproduction in black-and-white, please supply black-and-white versions of the figures for printing purposes.

For any further information please visit our customer support site at <http://support.elsevier.com>.

### **Additional information**

Authors can suggest figures to the Editor for use as the *cover figure* for an issue. Cover figures should be in color and include data or a schematic model. There will be no charge to the authors for printing the color figure on the journal cover.

## **AFTER ACCEPTANCE**

### **Use of the Digital Object Identifier**

The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the journal *Physics Letters B*):

<http://dx.doi.org/10.1016/j.physletb.2010.09.059>

When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to change.

### **Online proof correction**

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

### **Offprints**

The corresponding author, at no cost, will be provided with a personalized link providing 50 days free access to the final published version of the article on [ScienceDirect](http://www.sciencedirect.com). This link can also be used for sharing via email and social networks. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's WebShop (<http://webshop.elsevier.com/myarticleservices/offprints>). Authors requiring printed copies of multiple articles may use Elsevier WebShop's 'Create Your Own Book' service to collate multiple articles within a single cover (<http://webshop.elsevier.com/myarticleservices/booklets>).

### **Additional information**

**US National Institutes of Health (NIH) voluntary posting ("Public Access") policy.**



Elsevier facilitates author response to the NIH voluntary posting request (referred to as the NIH "Public Access Policy"; see <http://www.nih.gov/about/publicaccess/index.htm>) by posting the peer-reviewed author's manuscript directly to PubMed Central on request from the author, 12 months after formal publication. Upon notification from Elsevier of acceptance, we will ask you to confirm via e-mail (by e-mailing us at [NIHauthorrequest@elsevier.com](mailto:NIHauthorrequest@elsevier.com)) that your work has received NIH funding and that you intend to respond to the NIH policy request, along with your NIH award number to facilitate processing. Upon such confirmation, Elsevier will submit to PubMed Central on your behalf a version of your manuscript that will include peer-review comments, for posting 12 months after formal publication. This will ensure that you will have responded fully to the NIH request policy. There will be no need for you to post your manuscript directly with PubMed Central, and any such posting is prohibited.

## **AUTHOR INQUIRIES**

You can track your submitted article at [http://help.elsevier.com/app/answers/detail/a\\_id/89/p/8045/](http://help.elsevier.com/app/answers/detail/a_id/89/p/8045/). You can track your accepted article at <http://www.elsevier.com/trackarticle>. You are also welcome to contact Customer Support via <http://support.elsevier.com>.

© Copyright 2014 Elsevier | <http://www.elsevier.com>